New pharmaceuticals


The Danish Medicines Council assesses whether to recommend new drugs and new indications of an existing pharmaceutical as a standard treatment at Danish hospitals. Amgros negotiates prices of new pharmaceuticals.

If a new drug is to be considered as a standard treatment at Danish public hospitals, the Danish Medicines Council has to assess it first. In the application process, the supplier has to document that the pharmaceutical contributes added value compared with the existing treatment. The Medicines Council recommends the drug if there is a reasonable match between the added value and the additional costs the product entails.

Since 1 January 2020, the Danish Medicines Council has taken over from Amgros the task of assessing whether applicants’ cost analyses are valid and relevant.

The Medicines Council still also assesses the added clinical value of the drug. The results provide a basis for price negotiations with suppliers.

The Danish Medicines Council assesses whether there is a reasonable match between the added value and additional costs, after which the Council will decide whether it will recommend the pharmaceutical as a possible standard treatment.

Read more about the application process at the Danish Medicines Council here.


Health economic analyses taken over by the Danish Medicines Council

Since 1 January 2020, the Danish Medicines Council Secretariat has taken over the task of assessing health economic analyses in connection with recommendations by the Danish Medicines Council of new medicines and indicators.

This means that, in future, questions regarding the healtch economic part of applications for new medicines and indicators should be referred to the Danish Medicines Council Secretariat.

When the Danish Medicines Council has assessed the added clinical value, Amgros still negotiates the price of the medicine

Click here to read the article

Read more

New pharmaceuticals

Health economics

Is there is a reasonable relationship between the added clinical value from a new pharmaceutical compared with the existing treatment, and the costs this entails?

READ MORE
New pharmaceuticals

Negotiation of prices

When the Danish Medicines Council has determined the added clinical value of a new pharmaceutical, Amgros will negotiate with the applicant

READ MORE

Sune Lindgaard

Head of Business Intelligence and Health Economy

I’m responsible for operation and development of business intelligence and health economics. I make sure that our department can proudly claim to be the partner who gets things done.

Lasse Lund Gundtoft

Negotiator

I work as a negotiator for new pharmaceuticals and I coordinate Amgros' activities in relation to the Danish Medicines Council.